Should Lilly Investors Worry About Its Rival From Within
Eli Lilly dominates the GLP-1 space, but competition is heating up from outside and inside its own lineup. This guide...
Discover Eli Lilly stock insights from 4 articles covering long-term bets, timing questions, bullishness priced in, and FDA news. Learn what matters and refine portfolio today.
16 articlesEli Lilly dominates the GLP-1 space, but competition is heating up from outside and inside its own lineup. This guide...
Eli Lilly posts above-consensus Q1 results, lifting shares yet leaving the year-to-date narrative pressured by pricin...
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Eli Lilly is delivering big news for investors. The rallying force behind recent gains comes from GLP-1 drugs, manufa...
Investors are watching Eli Lilly as GLP-1 drugs like Mounjaro and Zepbound power growth. This article breaks down the...
Eli Lilly's ascent to the top of the drug charts centers on a single family of medicines. This article breaks down wh...
Lilly stock has faced pressure, but one key driver could keep it in buy territory. This article unpacks the core reas...
The VanEck PPH ETF faces two key risks in 2026: heavy concentration in Eli Lilly and shifting U.S. drug pricing polic...
Eli Lilly has faced a pullback that can create long-term buying opportunities. This guide explores using a budget-fri...
As April 10 approaches, investors debate whether Lilly stock is a buy. This guide breaks down catalysts, valuation, a...
Two pharma giants, two very different growth stories. This guide breaks down why Eli Lilly might be the best growth s...
The weight loss drug space has become a focus for growth-minded investors. This guide weighs Eli Lilly's proven progr...